CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 110 target
Drug / intervention
Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells. +1 morebiological
Likely dose
Not stated in record
Key inclusion· 9
  • Age older than 18 years
  • CCS Grade III or IV angina for ≥90 days despite maximal medical therapy
  • Maximally tolerated doses of ≥2 of 4 anti-anginal drug classes with stable regimen ≥2 months
  • No suitable options for CABG or PCI, or high-risk for revascularization
Key exclusion· 20
  • Recent (≤30 days) troponin or CKMB positive ACS (NSTEMI/STEMI)
  • Successful revascularization by CABG or PCI within 6 months
  • Unsuccessful PCI within 30 days
  • Predominant angina manifestation is dyspnoea

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05711849
NCT05711849Phase 2RecruitingOn TrackUpdated 5mo ago

A Phase II Randomised Sham-controlled Trial Assessing the Safety and Efficacy of Intracoronary Administration of Autologous Bone Marrow Cells in Patients With Refractory Angina

Barts & The London NHS Trust·interventional·Posted Feb 3, 2023·Updated Jan 7, 2026

In Brief

A Phase 2 clinical trial evaluating Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells. and Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath). for Refractory Angina Pectoris and Refractory Angina. Currently recruiting, targeting 110 participants across 1 site.

Detailed Summary

REGENERATE-COBRA will examine whether autologous stem cell treatment can improve angina symptoms and quality of life for patients with refractory angina. Patients will be randomised (randomly allocated with a 50:50 chance) to either the 'treatment' or the 'sham' group - they will not know which group they are in. In the 'treatment' group: * Stem cells will be collected from bone marrow in the patient's hip under local anaesthetic (a bone marrow aspiration). * Under local anaesthetic, the stem cells will be infused into the arteries that supply blood to the heart through a small tube inserted either in the wrist or the groin. * The follow-up involves a phone call at 1 month and 12 months and clinic visit at 6 months. In the 'sham' group: * A sham bone marrow aspiration is performed - a 3mm nick in the skin will be made under local anaesthetic. * A sham cell infusion is performed - a small tube is inserted either in the wrist or groin under local anaesthetic. * The follow-up involves a phone call at 1 month and 12 months and clinic visit at 6 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2Recruiting
2023202420252026
First PostedFeb 3, 2023
Enrollment StartMar 1, 2024
Primary CompletionAug 31, 2026
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 3.4 years agoPrimary completion in 2 months

Interventions

Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells.biological

Bone marrow will be harvested from the posterior superior iliac crest under local anaesthetic, and mononuclear cells will be separated using a Ficoll technique in a certified laboratory. Later that same day, the participant will undergo an intracoronary cell infusion of the mononuclear cells. Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the bone marrow aspiration and cell infusion).

Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).procedure

These participants will have a sham bone marrow aspiration (a 3mm incision in the skin under local anaesthetic) and a sham intracoronary infusion procedure (the insertion of radial or femoral sheath under local anaesthetic). Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the sham bone marrow aspiration and sham cell infusion).